文献速递心境障碍

选择性5-羟色胺再摄取抑制剂在无副作用时对成人抑郁症的疗效:西酞普兰与帕罗西汀的超级分析

Efficacy of selective serotonin reuptake inhibitors in the absence of side effects: a mega-analysis of citalopram and paroxetine in adult depression.
PubMed 文献 · Mol Psychiatry · 2017-07-25

该研究基于15项FDA注册的安慰剂对照试验的患者水平事后分析,比较无早期不良事件的活性药物完成者与安慰剂完成者的HDRS抑郁情绪条目减分。西酞普兰和帕罗西汀的效应量分别为0.48和0.33,且不良事件严重程度不预测疗效,不支持抗抑郁药优于安慰剂仅因副作用的假说。

要点

  • 无早期不良事件时,西酞普兰和帕罗西汀仍显著优于安慰剂。
  • 效应量:西酞普兰0.48,帕罗西汀0.33(HDRS抑郁情绪条目)。
  • 不良事件严重程度与疗效无关联,反驳副作用驱动假说。

核心结论

  • 西酞普兰和帕罗西汀在不产生不良事件时仍明显优于安慰剂,且不良事件严重程度与疗效无关,反对抗抑郁药仅或主要因副作用而优于安慰剂的理论。

研究设计与样本

  • 患者水平事后分析,纳入所有由产业资助、FDA注册的西酞普兰或帕罗西汀治疗成人重性抑郁的安慰剂对照试验,使用HDRS且包含第6周症状评估(n=15)。

主要发现

  • 主要分析比较无早期不良事件的活性治疗完成者与安慰剂完成者(伴或不伴不良事件),HDRS抑郁情绪条目减分显示活性治疗组更大,效应量西酞普兰0.48、帕罗西汀0.33。
  • 报告早期不良事件的活性治疗者亦优于安慰剂组,且不良事件严重程度不预测应答。
  • 多项敏感性分析(如使用HDRS-17总分变化、排除所有不良事件者、意向性治疗人群)均与主要分析一致。

临床怎么用

  • 临床中不应仅因患者未出现早期副作用而否定抗抑郁药疗效,无副作用时药物仍可能有效。

局限性

  • 为事后分析,仅纳入西酞普兰和帕罗西汀的产业资助FDA注册试验,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

It has been suggested that the superiority of antidepressants over placebo in controlled trials is merely a consequence of side effects enhancing the expectation of improvement by making the patient realize that he/she is not on placebo. We explored this hypothesis in a patient-level post hoc-analysis including all industry-sponsored, Food and Drug Administration-registered placebo-controlled trials of citalopram or paroxetine in adult major depression that used the Hamilton Depression Rating Scale (HDRS) and included a week 6 symptom assessment (n=15). The primary analyses, which compared completers on active treatment without early adverse events to completers on placebo (with or without adverse events) with respect to reduction in the HDRS depressed mood item showed larger symptom reduction in patients given active treatment, the effect sizes being 0.48 for citalopram and 0.33 for paroxetine. In actively treated subjects reporting early adverse events, who also outperformed those given placebo, the severity of the adverse events did not predict response. Several sensitivity analyses, for example, including (i) those using change of the sum of all HDRS-17 items as effect parameter, (ii) those excluding all subjects with adverse events (that is, also those on placebo) and (iii) those based on the intention-to-treat population, were all in line with the primary analyses. The finding that both paroxetine and citalopram are clearly superior to placebo also when not producing adverse events, as well as the lack of association between adverse event severity and response, argue against the theory that antidepressants outperform placebo solely or largely because of their side effects.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Hieronymus F, Lisinski A, Nilsson S, et al. Efficacy of selective serotonin reuptake inhibitors in the absence of side effects: a mega-analysis of citalopram and paroxetine in adult depression. Mol Psychiatry. 2017. PMID: 29155804. doi:10.1038/mp.2017.147

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。